SynthesisPituitary2014
Clinical and biochemical characteristic features of metastatic cancer to the sella turcica: an analytical review.
Synthesis in Pituitary, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.
- Current status and treatment modalities in metastases to the pituitary: a systematic review.Journal of neuro-oncology · 2020Pooled it
- Article
- Review
- Central Diabetes Insipidus as a Rare Presentation of Small Cell Lung Cancer: A Case Report.Cureus · 2026Article
- Article
- Malignant melanoma with pituitary metastasis: A case report and literature review.Frontiers in endocrinology · 2025Review
- Solitary isolated disseminations of glioblastoma to sellar and suprasellar regions: two case reports.Acta neurochirurgica · 2024Article
- Wrong Tissue at the Wrong Place: A Rare Case of Hypopituitarism Secondary to Metastatic Renal Cell Carcinoma.Cureus · 2024Article
- Metastases to the pituitary gland: insights from the German pituitary tumor registry.Pituitary · 2023Article
- Aggressive Pituitary Tumors and Pituitary Carcinomas: From Pathology to Treatment.The Journal of clinical endocrinology and metabolism · 2023Article
- Neoplasms and tumor-like lesions of the sellar region: imaging findings with correlation to pathology and 2021 WHO classification.Neuroradiology · 2023Review
- Diabetes Insipidus due to Metastases of Undiagnosed Lung Cancer: A Case Report from Syria.Case reports in endocrinology · 2023Article
- The role of stereotactic radiosurgery in the multidisciplinary management of pituitary metastases.Pituitary · 2022Article
- Polyuria and polydipsia revealing a pituitary metastasis: Report of a rare case.Clinical case reports · 2022Article
- Masked diabetes insipidus in pituitary metastasis from breast cancer after thalamic biopsy: a case report.Journal of medical case reports · 2022Article
- Evolution in endoscopic endonasal approach for the management of hypothalamic-pituitary region metastasis: A single-institution experience.Frontiers in oncology · 2022Article
- Secondary mutant ALK-I1171s in pituitary metastases from a patient with ALK fusion-positive advanced lung adenocarcinoma: A case report and literature review.Frontiers in oncology · 2022Article
- Pituitary metastases from neuroendocrine neoplasms: case report and narrative review.Pituitary · 2021Review
- Article
- Pituitary Metastasis of Lung Neuroendocrine Carcinoma Mimicking Pituitary Adenoma:Case Report and Literature Review.Frontiers in endocrinology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesSellar metastasis is uncommon and poorly characterized as published data include small series of subjects. This study's goal is to identify unique features that differentiate this entity from other sellar masses such as pituitary macroadenomas.
methodsPublished cases of pathologically-confirmed sellar metastasis along with our experience in such patients over a 6-years period were reviewed (total = 129). As a control group, we reviewed similar data on 55 patients with pituitary macroadenomas managed over the same time-period. Presenting symptoms, pituitary dysfunction were analyzed using univariate, multivariate and receiver operating characteristic (ROC) analyses.
resultsSellar metastasis has equal gender distribution with a median patient-age of 56 years. The most common primary malignancy was breast cancer (29%) in women and lung cancer (30%) in men. Sellar metastasis was the first manifestation of cancer in over 40% of patients. Common presenting symptoms included headaches, visual field deficits, abnormal eye motility and diabetes insipidus. These symptoms were less frequent among patients with pituitary macroadenomas. Univariate regression analyses showed that headaches, abnormal eye motility, visual field deficits and diabetes insipidus were each predictive of metastatic disease. ROC analysis combining all 4 features revealed an AUC of 0.953 with a sensitivity of 0.818 and a specificity of 0.935. Using the multivariate regression, abnormal eye motility and/or diabetes insipidus independently predicted metastatic disease.
conclusionsSellar metastasis should be suspected in patients presenting with sellar masses, abnormal eye motility and/or diabetes insipidus even those without known malignancy since pituitary metastasis can often be the first manifestation of cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.